Edwards Lifesciences Corp. (EW) News
Filter EW News Items
EW News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EW News Highlights
- For EW, its 30 day story count is now at 35.
- Over the past 24 days, the trend for EW's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- API, ED and MA are the most mentioned tickers in articles about EW.
Latest EW News From Around the Web
Below are the latest news stories about EDWARDS LIFESCIENCES CORP that investors may wish to consider to help them evaluate EW as an investment opportunity.
Edwards Lifesciences Full Year 2022 Earnings: EPS Beats ExpectationsEdwards Lifesciences ( NYSE:EW ) Full Year 2022 Results Key Financial Results Revenue: US$5.38b (up 2.9% from FY 2021... |
Edwards Lifesciences Surges As Signs Point To 'Green Shoots Around The Corner'There are signs of green shoots around the corner for Edwards Lifesciences, an analyst said Wednesday as EW stock surged. |
Edwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call TranscriptEdwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call Transcript January 31, 2023 Operator: Greetings, and welcome to the Edwards Lifesciences Fourth Quarter 2022 Earnings Conference Call. Please note, this conference is being recorded. I will now turn the conference over to our host, Mark Wilterding, Senior Vice President of Investor Relations and Treasurer. Thank you. […] |
Edwards Lifesciences (EW) Q4 Earnings Top, Margins IncreaseEdwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe. |
Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023Edwards Lifesciences Corp (NYSE: EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61. The company reported Q4 revenues of $1.35 billion, up 1% and 7% on constant currency, beating the consensus of $1.33 billion. While TAVR sales remained flat year over year, Edwards reported 1% growth for its structural heart business. It attributed that bump to its Resilia technologies launch and Mitris surgical mitral valve. Outlook: Edwards Lifesciences reaffirmed its FY23 |
Edwards Lifesciences (EW) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
Edwards Lifesciences (EW) Q4 Earnings and Revenues Surpass EstimatesEdwards Lifesciences (EW) delivered earnings and revenue surprises of 4.92% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTSEdwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. |
A Preview Of Edwards Lifesciences''s EarningsEdwards Lifesciences (NYSE: EW ) is set to give its latest quarterly earnings report on Tuesday, 2023-01-31. Here''s what investors need to know before the announcement. Analysts estimate that Edwards Lifesciences will report an earnings per share (EPS) of $0.61. Edwards Lifesciences bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com |
Edwards Lifesciences Q4 2022 Earnings PreviewEdwards Lifesciences (EW) is scheduled to announce Q4 earnings results on Tuesday, January 31st, after market close.The consensus EPS Estimate is $0.61 (+19.6% Y/Y) and the… |